About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/16/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/16/2021.

Feasibility of a Culturally-Specific Video Text Cessation Intervention With AA Quitline Callers

Clinicaltrials.gov identifier NCT03927976

Recruitment Status Completed

First Posted April 25, 2019

Last update posted March 16, 2020

Study Description

Brief summary:

Assess the feasibility and acceptability of delivering an mHealth tobacco intervention among state quitline enrollees.

  • Condition or Disease:Tobacco Use Cessation
  • Intervention/Treatment: Behavioral: Path2Quit - culturally specific text message intervention
  • Phase: N/A
Detailed Description

The main objective of this study is to assess the feasibility of delivering an mHealth tobacco intervention among state quitline enrollees. This will be measured through the assessment of interest and willingness to use the video text program, and the ability to receive video text messages (i.e., has technology capable of receiving and viewing video texts. At the end of the intervention, the team will assess satisfaction and perceived helpfulness of the video-text messaging program as an indication of acceptability.

Study Design
  • Study Type: Interventional
  • Actual Enrollment: 35 participants
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Supportive Care
  • Official Title: Testing the Feasibility of a Culturally-Specific Video Text Cessation Intervention With African American Quitline Callers
  • Actual Study Start Date: April 2019
  • Actual Primary Completion Date: December 2019
  • Actual Study Completion Date: February 2020
Arms and interventions
Arm Intervention/treatment
Experimental: Path2Quit
After assessment eligibility, given consent, information about text messaging will be collected and participants enrolled in the Path2Quit culturally specific text message program and feedback will be collected on their experience.
Behavioral: Path2Quit - culturally specific text message intervention
SMS text delivers over 6 weeks with links to 20-120 second video clips from PTF. The message library contains 155 videos and assessment questions. First message is tailored to wake-up times, and the topic of the video (e.g., Never Quit Quitting) accompanies the text. Messages are pushed to participants 1-2 times/day, with 24/7 access to messages pulled from 3 keywords (HELP1, JONES, SLIP). Participants also receive inquiry texts, designed to push videos of interest/relevance to the individual. The cultural adaptations are infused throughout the video segments. Topics include deep structure: race and smoking in general, African American smoking statistics; norms for smoking; concerns about nicotine replacement/medication; family/collectivism; unique stressors; racism/discrimination, depression; co-morbid addiction; neighborhood/environmental influences; menthol cigarettes; race-specific weight issues and concerns; and working as a community against the tobacco industry.
Outcome Measures
  • Primary Outcome Measures: 1. Feasibility as measured by interest in using Path2Quit video text program [ Time Frame: Through study completion, an average of 6-weeks. ]
    The program will be evaluated as feasible if 50% of those screened are eligible and interested in the video text program AND if 90% of those who are eligible and interested in the video text program will be able to engage in the program (some may need technical assistance).
  • Secondary Outcome Measures: 1. Acceptability of intervention in terms of its Satisfaction and perceived helpfulness: 6-Week Follow-Up Questionnaire [ Time Frame: 6 weeks from end of intervention ]
    Acceptability of intervention measured through a 6-Week Follow-Up Questionnaire assessing satisfaction with Path2Quit and perceived usefulness Program will be evaluated as 'acceptable' if 80% of those who engage in the video text program and who answer the follow-up survey will rate their satisfaction with program and usefulness of the program at 3 or higher (on 0-7 scale where 3 indicates somewhat satisfied and somewhat useful) AND 80% rate the likelihood that they would recommend to a friend at a 3 or higher (on 0-7 point scale where 3 indicates "yes, I think so").
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- Self-identify as African American

- Enrolled in state quitlines within the past 3 months

- Have access to SMS texting

Exclusion Criteria:

- Does not meet inclusion criteria

Contacts and Locations
Contacts
Locations

United States, Ohio
Case Western Reserve University
Cleveland

Sponsors and Collaborators

Case Comprehensive Cancer Center

More Information
  • Responsible Party: Case Comprehensive Cancer Center
  • ClinicalTrials.gov Identifier: NCT03927976 History of Changes
  • Other Study ID Numbers: CASE1Y19
  • First Posted: April 25, 2019 Key Record Dates
  • Last Update Posted: March 16, 2020
  • Last Verified: March 2020
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No